Join
Live feed
·
PRReleasevia Quantisnow
Eledon Pharmaceuticals Inc. logo

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

ByQuantisnow·Wall Street's wire, on your screen.
ELDN· Eledon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELDN (Eledon Pharmaceuticals Inc.) and more on Quantisnow.